Company: SMNR
Filing Date: 2025-08-13
Form Type: 424B3
Source: 0001193125-25-179226
Chunk: 11

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: 424B3
Chunk 11
---
.                                                                                                                                                                                                                      |     |                                                                                                                                                                                                      |
| Jim Mao             |     | Jim Mao, a director of Denali, currently holds 20,000 Denali Class B Ordinary Shares. Upon the completion of the Business Combination, Jim Mao shall hold a total of 20,000 shares of New Semnur Common Stock.                     |     |                                                                                                                                                                                                      |
| You Sun             |     | You Sun, the Chief Financial Officer of Denali, currently holds 20,000 Denali Class B Ordinary Shares. Upon the completion of the Business Combination, You Sun shall hold a total of 20,000 shares of New Semnur Common Stock.    |     |                                                                                                                                                                                                      |
| Kevin Vassily       |     | Kevin Vassily, a director of Denali, currently holds 20,000 Denali Class B Ordinary Shares. Upon the completion of the Business Combination, Kevin Vassily shall hold a total of 20,000 shares of New Semnur Common Stock.         |     |                                                                                                                                                                                                      |
| Denali Underwriters |     | Pursuant to the Deferred Discount Agreement, the Denali Underwriters are expected to receive the Common Stock Consideration upon closing of the Business Combination.                                                              |     | Remaining $2,021,250 of the aggregate Deferred Discount are expected to remain payable to the Denali Underwriters at the Closing in cash in accordance with the terms of the Underwriting Agreement. |

vii

Conflicts of Interest Since the Sponsor, its affiliates, representatives and the officers and directors of Denali (the “Sponsor Persons”), have interests that are different, or in addition to (and which may conflict with), the interests of the other holders of Denali Class A Ordinary Shares, a conflict of interest may exist in determining whether the Business Combination with Semnur is appropriate. Such interests include that the Sponsor Persons will lose their entire investment in Denali if Denali does not complete a business combination. When you consider the recommendation of the Denali Board in favor of approval of the Business Combination Proposal and the other proposals, you should keep in mind that the Sponsor Persons have interests in such proposal that are different from, or in addition to (which may conflict with), those of the Denali shareholders generally. These conflicts of interest include, among other things, the interests listed below:

| • |     | If Denali is unable to complete a business combination within the required time period, the aggregate dollar                                                                                                                                  
 amount of non-reimbursable funds the Sponsor and its affiliates have